946 CGP 42446-phase I study of a new bisphosphonate in patients with osteolytic bone metastases
| Autor: | Harold A. Harvey, E. Givant, J. Berenson, J. Seaman, Allan Lipton, M. Kowalski, L. Rosen, R. Knight |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Cancer Research
medicine.medical_specialty business.industry Nausea medicine.medical_treatment Urology Calvaria macromolecular substances Bisphosphonate Surgery Phase i study carbohydrates (lipids) medicine.anatomical_structure Oncology Toxicity medicine Vomiting Chills In patient medicine.symptom business |
| Zdroj: | European Journal of Cancer. 31:S197 |
| ISSN: | 0959-8049 |
| DOI: | 10.1016/0959-8049(95)96195-j |
| Popis: | CGP 42446, a third generation bisphosphonate, is two orders of magnitude more potent than Pamidronate in inhibiting 1.25 (OH)2 D3 induced release of calcium from mouse calvaria in vitro. Twenty-three patients with osteolytic bone metastases have been included in this Phase I trial. Patients received: 100 ug (7 pts.), 200 ug (6 pts.), 400 ug (7 pts.), or 800 ug (3 pts.) IV over 15 minutes q month. Patient entry continues and will include patients treated at 1500 and 2000 ug q month. No hematologic or biochemical toxicity has been observed. Side effects were mild (Grade I) and included eye irritation (3 pts.), nausea or fatigue (2 pts.), and flu-like symptoms, chills and vomiting (1 pt. each). Data on pyridinium crosslinks and C- and N- telopeptides will be presented. We conclude that CGP 42446 is a well tolerated new third generation bisphosphonate. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect